Cyclophilin A (CypA), a well-recognized receptor for antiinflammatory drug cyclosporine A (CsA) is a ubiquitous and multifunctional protein. Beside the diverse intracellular functions, CypA is secreted against inflammatory stimuli, where it activates and attracts leukocytes via CD147 to the stimulus site. Interestingly, it synergizes with other factors to induce leukocyte migration in different animals. However, the silencing and inhibition of CypA or CD147 inhibits leukocytes chemotaxis and inflammation. This review focuses on the advances made in understanding the mechanism of CypA-dependent leukocytes chemotaxis and hence, recognition of this factor as a possible therapeutic target in inflammatory diseases.
Introduction
CypA, a key member of the immunophilins family, is evolutionarily conserved and ubiquitously expressed in both prokaryotic and eukaryotic cells [1, 2] . CypA, also called PPIase, catalyzes the cis-trans isomerization of proline amidic peptide bonds, through which it regulates many biologic processes, including intracellular signaling, transcription, inflammation, and apoptosis [1, 3] . Initially, CypA was identified as a receptor for CsA [4, 5] , and the CypA-CsA complex was shown to inhibit the function of calcineurin [6] . Later, the CypA role became prominent in protein folding, overhauling, and apoptosis [7, 8] . Furthermore, CypA was recognized as the most abundant member of the immunophilin family with a series of roles, such as protein trafficking, gene regulation, and T cell activation [9, 10] .
Besides the intracellular roles, CypA can be secreted in response to inflammatory stimuli, hypoxia, infection, and oxidative stress [10, 11] . Secreted CypA has an important role in viral infection [12] , periodontitis [13] , and atherosclerosis [14] .
CypA is reported to be associated with the prolactin receptor (cytokine) [15] and CXCR4 (chemokine) for its function under in vitro and in vivo conditions [1, 3, 16] . CypA also binds Sanglifehrin A and inhibits macrophage-activated ERK1/2, MAPK signaling, and hence, cell proliferation [17, 18] .
In the previous decade, the role of the CypA was highlighted in cellular migration and chemotaxis. CypA was thought to be involved in inflammatory diseases [19] , and it was able to upregulate CD147 (a receptor of CypA) in macrophages [20] , resulting in inflammation. However, complete understanding of the CypA-induced leukocyte chemotaxis is lacking. In the previous few years, many studies have been conducted to explore the chemotactic role of CypA for leukocytes in various animals, including human beings. It is a great concern to know its exact role and pave the path for further studies. Therefore, the current review will concentrate on the involvement of CypA in leukocyte activation and chemotaxis. The review will further explain how CypA can be the possible target for therapies in such inflammatory diseases. This report will be of interest for many of the immunologists working on diverse groups of animals.
MECHANISM OF CHEMOTAXIS AND LEUKOCYTE ACTIVATION
Chemokines and cytokines monitor the host immune response to inflammation in leukocytes. Chemokines are linked through G-protein-coupled receptors, resulting in migration/trafficking of leukocytes toward, and then extravasation in, the injured sites [21] [22] [23] . It suggests that chemokines play a key role in the initiation of the anti-inflammatory responses, hence protecting the host tissues from infection or injury [24] . However, prolonged overexpression of chemokines may result in chronic inflammation, septic shock, and RA [25] . Furthermore, accumulation of neutrophils in the infected tissue may lead to autoimmune and nonautoimmune inflammatory conditions [26] , which may lead to the onset of carcinogenic events [27] .
Leukocytes, endothelial cells, and vascular smooth muscle cells secrete CypA in response to inflammatory stimuli [28] [29] [30] , which guide neutrophils and eosinophil to the stimulus site in vitro and in vivo [31] . Extracellular CypA also has proinflammatory effects on endothelial cells by increasing their proliferation, migration, and invasion [14, 29] . The inflammatory cells express a transmembrane glycoprotein CD147, referred as an extracellular MMP inducer [19] . CD147 was identified as a T cell activationassociated antigen as a result of its evident up-regulation in activated T cells [32] . The CD147 is a potent cell surface receptor for CypA and hence, involved in the CypA signaling cascade that terminates in ERK activation and chemotaxis [31, 33] . CypA regulates cell-surface expression of CD147 via binding to the residue pro211 and probably to the residue pro180 of CD147 [34, 35] . The CypA-CD147 complex requires cell-surface heparan sulfate for optimal binding and signaling [31, 36] . The molecular structure of CD147 is different from typical chemokine receptors, such as CR, CCR, CXCR, and CX3CR. Therefore, extracellular CypA may have no chance to interact and synergize with chemokines [36, 37] . The internalization of CypA into the T cell is not well understood. However, after interacting with CD147, CypA enters into the cytoplasm of leukocytes, such as the T cell, where the PPIase active site of CypA establishes the complex with the SH2 domain of ITK. ITK, a nonreceptor tyrosine kinase expressed in T cells, has an important role in regulating several receptor-mediated signaling pathways, such as the TCR and chemokine receptor. Upon activation, ITK mediates the activation and mobilization of calcium and the NFAT transcription factor, which subsequently activates T cells [3, 38] . The N-terminal of CypA can also interact with the A-pocket of retinoblastoma susceptibility protein 105Rb, which functionally mediates NFAT and activates T cells (Fig. 1) [39] .
CypA SERVES AS A COFACTOR IN LEUKOCYTE CHEMOTAXIS
In addition to the individual role in chemotaxis, CypA synergizes with other factors to induce chemotaxis. CypA is involved as a cofactor with classic chemokine MIP-2 and the chemokine receptor CXCR4 in cell proliferation and migration [16, 22] . It is suggested that CD98 and CD147 might play role in CypA-induced T cell migration, which is closely related with p-ERK, p-ZAP70, p-CD3, and p-lymphocyte-specific protein tyrosine kinase signaling pathways (see [32] ). This suggests that CypA interacts with many other factors in the induction of chemotaxis. The knowledge of such CypA-associated factors will shed a new light on the mechanism of chemotaxis, and it will be a valuable additive to the CypA therapeutics in inflammatory processes.
CypA-INDUCED LEUKOCYTE CHEMOTAXIS
Secreted CypA, in response to inflammatory stimuli, oxidative stress, and inflammatory diseases, is a potent chemoattractant for leukocytes in different animals and cell lines [10, 11, 31, 40] . Elevated levels of CypA have been reported in several inflammatory diseases, including RA [41] and vascular smooth muscle disease [30] . In RA patients, overexpressed CypA upregulate the calcium-induced chemotaxis. The overexpressed CypA could directly bind with CD147, resulting in the invasive migration of neutrophils to bone joints, which eventually contributes to bone destruction [42] [43] [44] . The overexpression of CD147 also increases MMP secretion and invasion of synoviocytes [19, 45] . Subsequently, CypA-CD147 induces MMP-2 and MMP-9 secretion and promotes monocyte cell migration and invasion, leading to the overexpression of proinflammatory cytokine IL-8 in monocytes. All of these events may contribute to the cartilage and bone destruction in joints of the RA patients [46] . [28] [29] [30] . Secreted CypA interacts with residues pro211 and probably 180 of CD147 on the surface of T cells [34, 35] . The way of CypA internalization into the T cell is not fully understood. However, in the cytoplasm of T cells, CypA makes a stable complex with ITK and activates NFAT by a downstream signaling cascade. The NFAT eventually regulates gene expression in the nucleus and thus, activates the T cell [3, 38] . The silencing and inhibition of CypA decrease the leukocytes chemotaxis both in vitro and in vivo. PH, Pleckstrin homology; TH, Tec homology.
There is growing evidence that CypA plays a key role in the pathogenesis of periodontitis in animal models as well as in human patients. It may be involved in the inflammatory response of periodontal tissues through inducing the chemotaxis of PBMCs/neutrophils and the secretion of TNF-a/IL-8. CypA was overexpressed and localized with the infiltrating cells in inflamed connective tissues in gingival patients [13] .
CypA acts as a chemoattractant to monocytes, neutrophils, eosinophils, and T cells in acute [47] as well as chronic allergic asthma in mice [48] . This chemoattraction depends on the interaction of CypA with eosinophil cationic protein; hence, it induced leukocyte migration [48] . The acute lung inflammation in mice up-regulated the expression of the CypA accompanied by CD147-mediated neutrophil recruitment, resulting in neutrophilia of the lung tissues [40] .
The hydrodynamic injection of SHBs elevates the CypA level in mice, which causes the infiltration of inflammatory cells (lymphocytes) surrounding SHB-positive hepatocytes [49] . Hydrocortisone resistant thymocytes (EL-4) secrete CypA that induces migration of the bone marrow cell precursors of neutrophils, T and B cells, and dendritic cells of mice to the periphery [50] . Recently, rbCypA was shown to attract bovine peripheral blood granulocytes, monocytes, and lymphocytes [51] . The rCypA from channel catfish and Chinese yellow catfish had chemotactic activity for leukocytes in vitro [52, 53] . Interestingly, the secreted CypA in the skin mucus of Chinese yellow catfish also attracted leukocytes in a concentrationdependent manner [54] . Extracellular CypA also induced T cells chemotaxis both in vivo and in vitro [55] . This discussion suggests the potential role of CypA in chemotaxis in different animals and tissues. Further studies about the role of CypA in chemotaxis in other animals, developmental stages, and cell culture will help in fixing its temporal and spatial roles in inflammatory responses.
INHIBITION OF THE CHEMOTACTIC ACTIVITY OF CypA
In each case of CypA-induced chemotaxis, silencing CypA through RNA interference, CsA, or anti-CypA antibody treatment inhibited the process of leukocyte activation and chemotaxis [16] . For example, administration of anti-CD147 antibodies reduced cartilage erosion and synovitis in human RA patients, whereas in the mouse resulted in reduced neutrophilia and concurrent disease pathology [40, 56, 57] . Furthermore, a reduced inflammatory response of lymphocytes to SHB-positive hepatocytes and reduced chemotaxis in Jurkat T cells were observed after using CsA and anti-CD147 antibody [43, 49] .
The chemotactic activity of commercially available rCypA for monocytic THP-1 cells was prevented by CsA [58] . Substantial granulocyte migration toward rbCypA was inhibited by the addition of anti-bCypA antibody [51] . Leukocyte chemotaxis activity of CypA in the skin mucus of Chinese yellow catfish was also inhibited by the addition of anti-CypA antibodies [54] . All of this evidence proves the chemotaxis activity of CypA, which could be a promising target for therapy.
CONCLUSION AND FUTURE PERSPECTIVES
The role of CypA in the immune response is evident as a major factor, hence involved in inflammatory diseases, and can be targeted for anti-inflammatory therapies. Several factors associated with CypA have been identified. However, further studies will be required to explore other factors on the T cell surface, which can possibly be involved in the inflammatory mechanism. Furthermore, the role of CypA in activation of other leukocytes and the underlying molecular mechanism need to be elucidated. These discoveries will pave a new way for developing novel therapeutic inhibitors for inflammatory diseases. 
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